Efficacy of enterotoxigenicEscherichia colivaccine for bovine clinical mastitis

Abstract

An enterotoxigenic Escherichia coli (ETEC) vaccine designed to prevent diarrhoea was inoculated into dairy cows, and the occurrence of clinical mastitis was investigated for 2 years. Half of 480 cows in five farms were subcutaneously inoculated with ETEC vaccine (Imocolibov) twice with a 1-month interval in 2007 and 2008. Fisher's exact test and survival (time to event) analysis with the log-rank test were used to compare vaccinates and controls. In 2007, there was no significant difference in the incidence rate of mastitis between vaccinate (20.3%) and control (17.1%) cows. The rate of death or culling due to mastitis was lower in vaccinated cows (7.4%) than in control cows (29.2%, P=0.07, Fisher's exact test; P=0.02, log-rank test). In 2008, there was no significant difference in both the incidence rate of mastitis and the rate of death or culling due to mastitis. Milk productivity was compared between vaccinates and controls in one farm. Multi-way analysis of variance (ANOVA) was performed for the amount of 4% fat-corrected milk, and there was no significant difference between vaccinates and controls. These results suggest that ETEC vaccine inoculation reduces death or culling due to mastitis, whereas no preventive effect on the development of mastitis was observed.

The combination of vaccines and adjuvants to prevent the occurrence of high incidence of infectious diseases in bovine

“…Additionally, the immune protection efficacy of the E. coli J5 vaccine tends to decrease during peak lactation in dairy cattle ( 97 ). Another study revealed that vaccination against enterotoxigenic Escherichia coli (ETEC) reduced death or culling due to mastitis, but did not have a preventive effect on the development of mastitis ( 98 ).…”

Effect of enterotoxigenic Escherichia coli vaccine on innate immune function of bovine mammary gland infused with lipopolysaccharide

“…These cows were fed a TMR and milked at 0900 and 1600 h. Seven cows were subcutaneously inoculated with 5 mL of ETEC vaccine (Imocolibov, Merial; Scientific Feed Laboratory Co. Ltd., Tokyo, Japan) 3 wk before LPS challenge, and the remaining 7 did not receive treatment. The ETEC vaccine used in this study was an inactivated aluminum hydroxide and saponin-added vaccine against neonatal colibacillosis of calves and lambs, supplied as a suspension for injection (Morimoto et al 2011). The daily milk yield just before LPS challenge was 40.2 ± 2.7 kg (mean ± SE) in vaccinated cows and 33.6 ± 5.2 kg in control cows.…”

“…In Europe and North America, mastitis vaccines developed from Escherichia coli O111:B4 strain J5 (Overbeek et al, 1987) or Salmonella typhimurium Re-17 mutant (McClure et al, 1994) have been investigated for their efficacy (Hogan and Smith, 2003;Wilson et al, 2007). A previous study reported the use of an inactivated enterotoxigenic Escherichia coli (ETEC) vaccine, designed to prevent diarrhea, and to reduce death and culling due to mastitis (Morimoto, et al, 2011).…”

Development and Efficacy Evaluation of an SP01-adjuvanted Inactivated Escherichia Coli Mutant Vaccine Against Bovine Coliform Mastitis

“…In the context of the current advocacy of resistance reduction initiatives, methods using biological agents against mastitis are being developed, including phage therapy, antimicrobial therapy, antibody therapy, nonspecific immune boosting prophylaxis and vaccine prophylaxis. In particular, to effectively prevent and control the occurrence of bovine mastitis and to prevent the further effects of antibiotics on the ecosystem, the development of new vaccines has become a critical research direction [19][20][21][22][23]. At present, bovine mastitis E. coli vaccine is available from the U.S. company Schotten and from the Spanish company Ophthalmology.…”